Eli Lilly’s Next Weight-Loss Drug Shows 54.1-Pound Loss
Eli Lilly’s experimental EloraTZP produced average weight loss of up to 54.1 pounds in an early-stage trial of people with obesity and Type 2 diabetes. The results arrive as the company raises its revenue outlook and faces a new classwide warning for its existing weight-loss drugs.

Eli Lilly’s next weight-loss drug produced average weight loss of up to 54.1 pounds at 48 weeks in an early-stage trial, the company reported at ObesityWeek on November 14 and 15. The treatment, EloraTZP, was tested in people with obesity and Type 2 diabetes.
EloraTZP is not yet approved. The drug combines tirzepatide, the active ingredient in Lilly’s Zepbound and Mounjaro, with an experimental drug called eloralintide.
Up to 77% of trial participants reached normal blood sugar levels. The study was a Phase 2 trial, an early stage of drug testing.
Lilly shares gained 25% this year, compared with a 19% rise for the Health Care Select Sector SPDR Fund over the same period. The stock also rose 9% in the preceding month and sat 8.6% below its record high of $1,475.25.
Retatrutide trials target other conditions
Lilly’s experimental retatrutide reduced sleep-related breathing disruptions by up to 60.6% at 80 weeks in a Phase 3 trial. In another late-stage trial, the drug reduced knee arthritis pain by up to 75.8% at 68 weeks.
Those studies tested the drug against health problems often linked to obesity. Phase 3 trials are a later stage of drug testing than the EloraTZP study.
Lilly held about 61% of the US market in the second quarter. It also accounted for about seven in 10 new Medicare patients starting weight-loss drugs.
FDA warning covers drug class
On November 9, the Food and Drug Administration required a new warning for all GLP-1 drugs, including Lilly’s Mounjaro and Zepbound. The warning concerns a rare eye condition that can cause sudden vision loss.
The regulator reviewed 126 clinical trials. It found about six cases a year for every 100,000 patients taking GLP-1 drugs, compared with about four among patients not taking them.
The FDA has not established that the drugs caused the condition. Lilly shares nevertheless stayed near their record highs after the warning.
Lilly raises revenue outlook
Lilly reported third-quarter 2026 revenue of $24.4 billion on October 29, an increase of 39% from a year earlier. Revenue exceeded analyst estimates by roughly $2 billion.
Adjusted earnings per share rose 7% to $7.48, beating the $6.26 consensus estimate. Mounjaro sales grew 65%, while Zepbound sales rose 49%.
The company raised its full-year revenue forecast to $91 billion to $92 billion from $85 billion to $87 billion. It trimmed its earnings-per-share outlook to $35 to $36 because of one-time charges tied to recent acquisitions.
Take the quizWhat Kind of Holiday Spender Are You? Take the Black Friday QuizStart →
Markets · FintechHow to Calculate Compound Interest: Formula, Examples and the Rule of 72
Lifestyle · Food & HealthNormal Blood Pressure Chart by Age: Healthy Ranges Explained
Lifestyle · Food & HealthWhat Is Raynaud’s Syndrome? Why Fingers Turn White in the Cold
Lifestyle · Food & Health4 Ways Walking After Meals Helps Your Body, Doctors Say




















